Limb Girdle Muscular Dystrophy Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight

Limb Girdle Muscular Dystrophy Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight
Limb Girdle Muscular Dystrophy Market
Limb Girdle Muscular Dystrophy companies are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.

(Albany, USA) DelveInsight’s “Limb Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Limb Girdle Muscular Dystrophy, historical and forecasted epidemiology as well as the Limb Girdle Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Limb Girdle Muscular Dystrophy market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Limb Girdle Muscular Dystrophy market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Limb Girdle Muscular Dystrophy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Limb Girdle Muscular Dystrophy market.

 

Request for a Free Sample Report @ Limb Girdle Muscular Dystrophy Market Forecast

 

Some facts of the Limb Girdle Muscular Dystrophy Market Report are:

  • According to DelveInsight, Limb Girdle Muscular Dystrophy market size is expected to grow at a decent CAGR by 2032.
  • Leading Limb Girdle Muscular Dystrophy companies working in the market are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.
  • Key Limb Girdle Muscular Dystrophy Therapies expected to launch in the market are SRP-6004, LION-101, BBP-418 (ribitol), and others.
  • On February 2024, Sarepta Therapeutics announced results of a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and non-ambulatory participants (Cohort 2).
  • On October 2023, aTyr Pharma, Inc. announced results of an Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies.
  • On April 2023, ML Bio Solutions announced results of an open label study in ambulatory and non-ambulatory subjects with LGMD2I (also known as LGMD R9) previously enrolled in the natural history Study MLB-01-001. This is a study to determine the safety and tolerability of ascending dose levels of BBP-418 in those subjects.

 

Limb Girdle Muscular Dystrophy Overview

Limb-girdle muscular dystrophy (LGMD) encompasses a group of genetic disorders characterized by progressive weakness and wasting of the muscles, primarily affecting the muscles around the shoulders and hips. It can manifest at any age, with onset typically occurring in childhood, adolescence, or adulthood. LGMD is caused by mutations in various genes responsible for muscle function and structure.

Limb-girdle muscular dystrophy (LGMD) Symptoms vary widely among individuals but often include difficulty rising from a seated position, climbing stairs, and lifting objects. As the disease progresses, individuals may experience muscle weakness and atrophy in other areas of the body, leading to mobility limitations and potential respiratory complications in severe cases.

Limb-girdle muscular dystrophy (LGMD) Diagnosis involves a combination of clinical evaluation, genetic testing, electromyography (EMG), and muscle biopsy. While there is currently no cure for LGMD, management focuses on symptom relief, maintaining mobility, and optimizing quality of life. This may involve physical therapy, assistive devices, respiratory support, and ongoing monitoring for potential complications.

Research into potential treatments, including gene therapy and pharmacological interventions, is ongoing and offers hope for improved outcomes in the future. Additionally, supportive resources and patient advocacy organizations play a crucial role in providing information, support, and community for individuals and families affected by Limb-girdle muscular dystrophy (LGMD).

 

Learn more about Limb Girdle Muscular Dystrophy treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

 

Limb Girdle Muscular Dystrophy Market 

The Limb Girdle Muscular Dystrophy market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Limb Girdle Muscular Dystrophy market trends by analyzing the impact of current Limb Girdle Muscular Dystrophy therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Limb Girdle Muscular Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Limb Girdle Muscular Dystrophy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight’s’ estimates, the limb girdle muscular dystrophy market in 7MM is expected to show a positive growth, during the forecast period (2023–2032), mainly attributed to anticipated launch of emerging therapy and the increasing cases of LGMD.

 

Limb Girdle Muscular Dystrophy Epidemiology 

The Limb Girdle Muscular Dystrophy epidemiology section provides insights into the historical and current Limb Girdle Muscular Dystrophy patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Limb Girdle Muscular Dystrophy market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Limb Girdle Muscular Dystrophy Epidemiology @ Limb Girdle Muscular Dystrophy Market Dynamics

 

Limb Girdle Muscular Dystrophy Drugs Uptake

This section focuses on the uptake rate of the potential Limb Girdle Muscular Dystrophy drugs recently launched in the Limb Girdle Muscular Dystrophy market or expected to be launched in 2019-2032. The analysis covers the Limb Girdle Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Limb Girdle Muscular Dystrophy Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Limb Girdle Muscular Dystrophy market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Currently, there is no known cure for LGMD. However, there are supportive therapies designed to manage and alleviate its symptoms. The approach to LGMD management is individualized, focusing on addressing specific symptoms that each patient experiences. Treatment options may involve physical and occupational therapy to enhance muscle strength and prevent contractures, the utilization of assistive devices like canes, braces, walkers, or wheelchairs to aid mobility, corrective surgery for skeletal issues like scoliosis, and regular monitoring of cardiac and respiratory health for potential complications associated with certain LGMD subtypes.

 

Limb Girdle Muscular Dystrophy Pipeline Development Activities

The Limb Girdle Muscular Dystrophy report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Limb Girdle Muscular Dystrophy key players involved in developing targeted therapeutics.

 

Limb-girdle Muscular Dystrophy Pipeline Therapies and Companies

  • SRP-6004: Sarepta Therapeutics, Inc.
  • LION-101: Asklepios Biopharmaceutical, Inc.
  • BBP-418 (ribitol): ML Bio Solutions, Inc.

 

Request for a sample report to understand more about the Limb Girdle Muscular Dystrophy pipeline development activities @ https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

 

Limb Girdle Muscular Dystrophy Therapeutics Assessment

Major key companies are working proactively in the Limb Girdle Muscular Dystrophy Therapeutics market to develop novel therapies which will drive the Limb Girdle Muscular Dystrophy treatment markets in the upcoming years are ML Bio Solutions, Asklepios BioPharmaceutical, Sarepta Therapeutics, Inc., Atamyo Therapeutics, Edgewise Therapeutics, Vita Therapeutics, BridgeBio Pharma, Hansa Biopharma, and others.

 

Learn more about the emerging Limb Girdle Muscular Dystrophy therapies & key companies @ https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market

 

Limb Girdle Muscular Dystrophy Report Key Insights

1. Limb Girdle Muscular Dystrophy Patient Population

2. Limb Girdle Muscular Dystrophy Market Size and Trends

3. Key Cross Competition in the Limb Girdle Muscular Dystrophy Market

4. Limb Girdle Muscular Dystrophy Market Dynamics (Key Drivers and Barriers)

5. Limb Girdle Muscular Dystrophy Market Opportunities

6. Limb Girdle Muscular Dystrophy Therapeutic Approaches

7. Limb Girdle Muscular Dystrophy Pipeline Analysis

8. Limb Girdle Muscular Dystrophy Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Limb Girdle Muscular Dystrophy Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Limb Girdle Muscular Dystrophy Competitive Intelligence Analysis

4. Limb Girdle Muscular Dystrophy Market Overview at a Glance

5. Limb Girdle Muscular Dystrophy Disease Background and Overview

6. Limb Girdle Muscular Dystrophy Patient Journey

7. Limb Girdle Muscular Dystrophy Epidemiology and Patient Population

8. Limb Girdle Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Limb Girdle Muscular Dystrophy Unmet Needs

10. Key Endpoints of Limb Girdle Muscular Dystrophy Treatment

11. Limb Girdle Muscular Dystrophy Marketed Products

12. Limb Girdle Muscular Dystrophy Emerging Therapies

13. Limb Girdle Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Limb Girdle Muscular Dystrophy Market Outlook (7 major markets)

16. Limb Girdle Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Limb Girdle Muscular Dystrophy Market

18. Limb Girdle Muscular Dystrophy Market Drivers

19. Limb Girdle Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services


Posted

in

by

Tags: